Impairment of phagocytic and T-cell-mediated antibacterial activity and plasma endotoxins in patients with untreated gastrointestinal cancer

Scandinavian Journal of Gastroenterology

Volumn 33, Issue 8, 1998, Pages 847-852

  Amati, L ^b   Caradonna, L ^b   Greco, B ^b   Leo, S ^b   Caccavo, D ^b   Jirillo, E ^a  

^a NATIONAL INSTITUTE FOR DIGESTIVE DISEASES   (Italy)

^b NONE

Author keywords

Cancer; Cytokines; Endotoxins; Phagocytosis; T cells

Indexed keywords

ENDOTOXIN;

ADULT; AGED; ANTIBACTERIAL ACTIVITY; ARTICLE; CANCER IMMUNOLOGY; CELLULAR IMMUNODEFICIENCY; CLINICAL ARTICLE; CONTROLLED STUDY; DIGESTIVE SYSTEM CANCER; FEMALE; HUMAN; MALE; MONOCYTE; PHAGOCYTE; PRIORITY JOURNAL; T LYMPHOCYTE;

ADULT; AGED; AMPULLA OF VATER; CASE-CONTROL STUDIES; COLORECTAL NEOPLASMS; COMMON BILE DUCT NEOPLASMS; CYTOKINES; DIGESTIVE SYSTEM NEOPLASMS; ENDOTOXINS; FEMALE; HUMANS; MALE; MIDDLE AGED; PHAGOCYTOSIS; STOMACH NEOPLASMS; T-LYMPHOCYTES;

EID: 0031689986     PISSN: 00365521     EISSN: None     Source Type: Journal    
DOI: 10.1080/00365529850171512     Document Type: Article

References (44)

1. McClain K. Immunodeficiency secondary to infiltrative disease and malignancy. In: Rich R, editor. Clinical immunology -principles and practice. St. Louis (MO): Mosby; 1996. p. 817-23.
2. Coker DD, Morris DM, Coleman JJ, Schimpft SC, Wiernik PH, Elias EG. Infection among 210 patients with surgically staged Hodgkin's disease. Am J Med 1983;75:97-109.
3. Passwell M, Levanon M, Davidsohn J, Ramot B. Monocyte PGE2 secretion in Hodgkin's disease and its relation to decreased cellular immunity. Clin Exp Immunol 1983;51:61-8.
4. Jirillo E, Miragliotta G, Caretto G, Cedola MC, Nappi R, Sansone LA, et al. Relationship between immune system and gram-negative bacteria. Acid treated Salmonella minnesota R595 (Re) enhances immune responsiveness in patients with gynecologic malignancies. Int J Immunopharm 1986;8:881-6.
5. Jirillo E, Tortorella C, Pellegrino NM, Antonaci S. Immunotherapy with thymic hormones in various diseases: a review. Biomed Lett 1995;52:113-25.
6. Tsunawaki S, Sporn M, Ding A, Nathan C. Deactivation of macrophages by transforming growth factor β. Nature 1988;334: 260-2.
7. Lagneaux L, Delforge A, Dorval C, Bron D, Stryckmans P. Excessive production of transforming growth factor-β by bone marrow stromal cells in B-cell chronic lymphocytic leukemia inhibits growth of hematopoietic precursor and interleukin-6 production. Blood 1993;82:2379-85.
8. Rohrer JW, Coggin JH Jr. CD8 T cell clones inhibit antitumor T cell function by secreting IL-10. J Immunol 1995;155:5719-27.
9. Nabioullin R, Sone S, Mizuno K, Yano S, Nishoka Y, Haku T, et al. Interleukin-10 is a potent inhibitor of tumor cytotoxicity by human monocytes and alveolar macrophages. J Leukoc Biol 1994;55:437-42.
10. Dummer W, Bastian BC, Ernst N, Schanzle C, Schwaaf A, Brocker EB. Interleukin-10 production in malignant melanoma: preferential detection of IL-10 secreting tumor cells in metastatic lesions. Int J Cancer 1996;66:507-10.
11. Gastl GA, Abrams JS, Nanus DM, Oosterkamp R, Silver J, Liu F, et al. Interleukin-10 production by human carcinoma cell lines and its relationship to interleukin-6 expression. Int J Cancer 1993;55:96-101.
12. Smith DR, Kunkel SL, Burdick MD, Wilke CA, Orringer MB, Whyte RI, et al. Production of interleukin-10 by human bronchogenic carcinoma. Am J Pathol 1994;145:18-25.
13. Fortis C, Foppoli M, Gianoti L, Galli L. Increased interleukin-10 serum levels in patients with solid tumors. Cancer Lett 1995; 104:1-5.
14. Gotlieb VH, Abrams JS, Watson JM, Velu TJ, Berek JS, Martinez-Maza O. Presence of interleukin-10 (IL-10) in the ascites of patients with ovarian and other intra-abdominal cancers. Cytokine 1992;4:385-90.
15. Barth RJ, Camp BJ, Martuscello TA, Dain BJ, Memoli VA. The cytokine microenvironment of human colon carcinoma. Lymphocyte expression of tumor necrosis factor-α and interleukin-4 predicts improved survival. Cancer 1996;78:1168-78.
16. Marino P, Cugno M, Preatoni A, Cori P, Rosti A, Frontini L, et al. Increased levels of soluble interleukin-2 receptors in serum of cancer patients. Br J Cancer 1990;61:434-5.
17. Murakami S, Satomi A, Ishida K, Murai H, Matsuki M, Hashimoto T. Serum-soluble interleukin-2 receptor concentrations in patients with gastric cancer. Cancer 1994;74:2745-8.
18. Rosenblatt HM. Immunodeficiencies associated with medical therapy. In: Rich R, editor. Clinical immunology - principles and practice. St. Louis (MO): Mosby; 1996. p. 824-35.
19. Boyum A. Isolation of mononuclear cells and granulocytes from human blood. Scand J Clin Lab Invest 1968;21 Suppl 97:77-89.
20. Kumagai K, Itoh K, Hinuma S, Tada M. Pretreatment of plastic Petri dishes with foetal calf serum. A simple method for macrophage isolation. J Immunol Meth 1979;29:17-25.
21. Mandell L, Hook WE. Leukocyte function in chronic granulomatous diseases of childhood. Am J Med 1969;47:473-8.
22. Antonaci S, Tortorella C, De Simone C, Jirillo E. Role of bacterial lipopolysaccharides in the development of natural antibacterial activity mediated by human peripheral blood T lymphocytes. Int Rev Immunol 1990;6:237-45.
23. Poole S, Dawson P, Gaines Das RE. Second international standard for endotoxin: calibration in an international collaborative study. J Endotoxin Res 1997;4:211-31.
24. Tagliabue A, Villa L, Boraschi D, Peri G, De Gori V, Nencioni L. Natural anti-bacterial activity against Salmonella typhi by human T4 + lymphocytes armed with IgA antibodies. J Immunol 1985;135:4178-82.
25. Tagliabue A, Nencioni L, Villa L, Keren DF, Lowell GH, Boraschi D. Antibody-dependent cell-mediated antibacterial activity of intestinal lymphocytes with secretory IgA. Nature 1983;306:184-6.
26. Jirillo E, De Simone C, Covelli V, Kiyono H, Mc Ghee JR, Antonaci S. LPS-mediated triggering of T lymphocytes in immune response against gram-negative bacteria. Adv Exp Med Biol 1990;256:417-25.
27. Mastroianni CM, Jirillo E, De Simone C, Grassi PP. Maffione AB, Catino AM, et al. Humoral and cellular immune responses to Salmonella typhi in patients with typhoid fever. J Clin Lab Anal 1989;3:191-5.
28. Jirillo E, Greco B, Caradonna L, Satalino R, Pugliese V, Cozzolongo R, et al. Evaluation of cellular immune responses and soluble mediators in patients with chronic hepatitis C virus (cHCV) infection. Immunopharmacol Immunotoxicol 1995;17: 347-64.
29. Jirillo E, Caradonna L, Greco B, Satalino R, Pugliese V, Sisto G, et al. Cellular immunity in steroid-treated patients with inflammatory bowel disease. Med Sci Res 1995;23:355-7.
30. Jirillo E, Caradonna L, Greco B, Satalino R, Pugliese V, Sisto G, et al. Circulating bacterial lipopolysaccharides (LPS) in patients with inflammatory bowel disease (IBD). Microecol Ther 1995;25:37-41.
31. Walken I, Owen RL. Intestinal harriers to bacteria and their toxins. Annu Rev Med 1990;41:393-400.
32. Van Deventer SJH, Pauw W, Tencate JW, Janssen ME, Büller HR, Sturk A. Clinical evaluation in febrile patients of an optimized endotoxin assay in blood. Prog Clin Biol Res 1987; 23:489-99.
33. Koll BS, Brown AE. Changing pattern of infections in the immunocompromised patient with cancer. Hematol Oncol Clin N Am 1993;7:753-69.
34. Bartholeyns J, Freudenberg M, Galanos C. Growing tumors induce hypersensitivity to endotoxin and tumor necrosis factor. Infect Immun 1987;55:2230-3.
35. Mackensen A, Galanos C, Weher V, Engelhardt R. Endotoxin tolerance: regulation of cytokine production and cellular changes in response to endotoxin application in cancer. Eur Cytokine Netw 1992;3:571-9.
36. Jirillo E (guest editor). Immunomodulation by the lipid A entity of bacterial lipopolysaccharides. Int Rev Immunol 1990;6:207-73.
37. Morrison DC, Danner RL, Dinarello CA, Munford RS, Natanson C, Pollack M, et al. Bacterial endotoxins and pathogenesis of gram-negative infections: current stains and future directions. J Endotoxin Res 1994;1:71-83.
38. Mosmann TR, Coffman RL. Th1 and Th2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu Rev Immunol 1989;7:145-73.
39. Oriss TB, Mc Carthy SA, Morel BF, Campana MAK, Morel PA. Crossregulation between T helper cell (Th1 and Th2). Inhibition of Th2 proliferation by IFN-γ involves interference with IL-1. J Immunol 1997;158:3666-72.
40. Powrie F, Coffman RL. Cytokine regulation of T-cell function: potential for therapeutic intervention. Immunol Today 1993;14: 270-2.
41. Aruga A, Aruga E, Tanigawa K, Bishop DK, Sondak VK, Chang AE. Type 1 versus type 2 cytokine release by Vβ T cell subpopulations determines in vivo antitumor reactivity. IL-10 mediates a suppressive role. J Immunol 1997;159:664-73.
42. Qin Z, Noffz G, Mohaupt M, Blankenstein T. Interleukin-10 prevents dendritic cell accumulation and vaccination with granulocyte-macrophage colony-stimulating factor gene-modified tumor cells. J Immunol 1997;159:770-6.
43. Curfs JHAJ, Meis JFGM, Hoogkamp-Korstanje AA. A primer on cytokines: sources, receptors, effects, and inducers. Clin Microbiol Rev 1997;10:742-80.
44. Chandra RK. Micronutrients and immune functions, an overview. Ann NY Acad Sci 1990;587:9-16.